Diffuse Large B Cell Lymphoma, Extranodal Lymphoma, Lymphoma
Conditions
Keywords
Lymphoma, Extranodal
Brief summary
The aim of this study is to prospectively collect clinical information of patients with extranodal DLBCL, assess the effectiveness of treatment for extranodal DLBCL in the real world, and explore the optimal treatment strategies in real-world populations.
Detailed description
DLBCL is a highly common aggressive non-Hodgkin's lymphoma. For specific extranodal sites of DLBCL, traditional chemotherapy protocols often cannot provide satisfactory results for patients. The aim of this study is to prospectively collect clinical information of patients with extranodal DLBCL, including the distribution of involved sites (such as central nervous system, testes, skin, breast, gastrointestinal tract, etc.), prognosis of diffuse large B-cell lymphoma with involvement of different extranodal sites, genetic mutation characteristics, correlation with molecular subtypes, impact of different treatment regimens on efficacy, assess the effectiveness of treatment for extranodal DLBCL in the real world, and explore the optimal treatment strategies in real-world populations.
Interventions
No interventions need to be specified for this study
Sponsors
Ruijin Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. ≥ 18 years (including 18 years). * 2\. Pathologically diagnosed with diffuse large B-cell lymphoma according to the 2016 WHO classification, including non-specific types and various special subtypes. * 3\. Newly diagnosed DLBCL with involvement of extranodal organs. * 4\. Patients who have received clinical treatment for lymphoma. * 5.Patients with measurable lesions, including at least one effective efficacy assessment.
Exclusion criteria
* 1\. Patients receiving supportive care only. * 2\. Patients who cannot obtain effective efficacy assessment data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Time Frame: Baseline up to data cut-off (up to approximately 1 year) | Overall Survival (OS) will be defined from the start date of therapy to the date of death from any cause. |
| Progression Free Survival (PFS) | Time Frame: Baseline up to data cut-off (up to approximately 1 year) | Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical characteristics form | Baseline up to data cut-off (up to approximately 1 year) | Clinical characteristics from data filled into registry forms by physicians and data managers, including but not limited to values of lactate dehydrogenase, clinical stage, performance status, age ≥ 60 years and number and location of extranodal localizations. |
Countries
China
Outcome results
None listed